Illinois is currently home to 2642 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Chicago, Peoria, Springfield and Urbana. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Trial-Ready Cohort-Down Syndrome (TRC-DS)
Recruiting
The purpose of the Trial-Ready Cohort - Down Syndrome (TRC-DS) is to enroll 120 healthy adults with Down syndrome (DS), between the ages of 25-55, into a trial ready cohort (TRC), and up to 450 participants in total including co-enrolled in the Alzheimer Biomarkers Consortium - Down Syndrome (ABC-DS) study. Participants enrolled in the TRC-DS will undergo longitudinal cognitive and clinical assessment, genetic and biomarker testing, as well as imaging and biospecimen collection. Using these outc... Read More
Gender:
ALL
Ages:
Between 25 years and 55 years
Trial Updated:
05/30/2025
Locations: Advocate Medical Group Adult Down Syndrome Center, Park Ridge, Illinois
Conditions: Down Syndrome, Alzheimer Disease, Dementia
Assessment Intravenous Site Events During Outpatient Infusion Procedures With a Wireless Thermal Measurement Device During
Recruiting
This study evaluates a Non-invasive Thermal Infusion Site Monitor (NTISM) device when used during routine outpatient infusion treatments.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
05/29/2025
Locations: Infusacare, Skokie, Illinois
Conditions: IV Infiltration, IV Extravasation
Assessment of CSF Shunt Flow and Headaches With a Thermal Measurement Device
Recruiting
This study evaluates the performance of a device for non-invasively assessing cerebrospinal fluid (CSF) shunt flow over multiple measurements performed by a study subject during headache and non-headache periods.
Gender:
ALL
Ages:
Between 6 years and 80 years
Trial Updated:
05/29/2025
Locations: Rhaeos, Inc, Chicago, Illinois
Conditions: Hydrocephalus
Safety and Immunogenicity of Stabilized CH505 TF chTrimer Vaccination in Adults Living With HIV-1 on Suppressive Antiretroviral Therapy
Recruiting
A5422 is a phase 1, randomized, double-blind, placebo-controlled clinical trial to assess the safety, tolerability, and immunogenicity of a vaccination with stabilized CH505 TF chTrimer admixed with 3M-052-AF + Aluminum hydroxide (Alum), to assess the effect of CH505 TF chTrimer vaccine as a therapeutic vaccine in adults living with HIV-1 on suppressive antiretroviral therapy (ART) with the aim of inducing new HIV-1 Envelope (Env) B-cell neutralizing immune responses. Participants will be on stu... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/29/2025
Locations: Northwestern University CRS, Chicago, Illinois
Conditions: HIV-1
First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor.
Recruiting
The purpose of this study is to determine the safety, blood concentrations and treatment effect of CRB-601 in combination with immunotherapy in patients who have advanced solid tumors (cancer) and have exhausted other therapeutic options.CRB-601 targets a protein called avb8 integrin which is expressed by some cancers and not others. This study will focus on tumor types which are know to highly or moderately express this protein. Researchers will evaluate the side effects caused by treatment, l... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/29/2025
Locations: University of Chicago, Chicago, Illinois
Conditions: Solid Tumor
A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors
Recruiting
The goal of this clinical trial is to define a safe and effective dose of CRB-701 for participants with solid tumors that are expressing a protein called nectin-4. The main questions it aims to answer are: What is the the safe and effective dose of CRB-701 when used alone? What cancers can be treated effectively with CRB-701? Participants will be asked to attend clinic and be given a intravenous infusion of CRB-701 on its own. They will have blood tests and other assessments to measure whethe... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/29/2025
Locations: University of Chicago, Chicago, Illinois
Conditions: Solid Tumor, Adult
Communication Bridge 3 Study
Recruiting
This study will use a randomized controlled trial design to evaluate the effect of two evidence-based treatments for adults with mild-moderate Primary Progressive Aphasia (PPA). The aim of the study is to help us better understand the effects of speech-language therapy on communication abilities in individuals with PPA.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
05/29/2025
Locations: University of Chicago - American School Building, Chicago, Illinois
Conditions: Primary Progressive Aphasia
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration
Recruiting
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration
Gender:
ALL
Ages:
60 years and above
Trial Updated:
05/29/2025
Locations: Illinois Retina Associates (01-037), Oak Park, Illinois
Conditions: Geographic Atrophy
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
Recruiting
The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-B01D1 in patients with Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/29/2025
Locations: Northwestern University Feinberg School of Medicine, Chicago, Illinois
Conditions: Non Small Cell Lung Cancer, Lung Cancer, Breast Cancer, Esophageal Cancer, Small Cell Lung Cancer, Nasopharyngeal Cancer, Head and Neck Squamous Cell Carcinoma
NVG-291 in Spinal Cord Injury Subjects
Recruiting
A Randomized, Double-Blind, Placebo-Controlled Phase 1b/2a Study of NVG-291 in Spinal Cord Injury Subjects
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
05/29/2025
Locations: Shirley Ryan AbilityLab, Chicago, Illinois
Conditions: Spinal Cord Injuries, Chronic Spinal Cord Injury, Subacute Spinal Cord Injury
A Study of Zigakibart in Adults With IgA Nephropathy
Recruiting
Safety and Efficacy of BION-1301 in Adults with IgA Nephropathy
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/29/2025
Locations: NorthShore University HealthSystem, Evanston, Illinois
Conditions: IgA Nephropathy, Immunoglobulin A Nephropathy
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
Recruiting
This phase III trial compares three-drug induction regimens followed by double-or single-drug maintenance therapy for the treatment of newly diagnosed multiple myeloma in patients who are not receiving a stem cell transplant and are considered frail or intermediate-fit based on age, comorbidities, and functional status. Treatment for multiple myeloma includes initial treatment (induction) which is the first treatment a patient receives for cancer followed by ongoing treatment (maintenance) which... Read More
Gender:
ALL
Ages:
All
Trial Updated:
05/29/2025
Locations: Saint Anthony's Health, Alton, Illinois
Conditions: Plasma Cell Myeloma